Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research.
The system is made up of an ion source integrated with breakthrough silicon microfluidic chips including M3 emitters and MEA chips. System models include the MnESI system with M3 emitters launched in November 2020, and the DuoESI system with M3 emitters and MEA chips launched in June 2022.
System performance has been validated by 8 customers' peer-reviewed papers, published in key industry journals like Analytical Chemistry and Journal of Chromatography A.
The success of the Newomics system has led to international co-marketing partnerships with Thermo Fisher Scientific and Bruker and collaborations with Agilent, Shimadzu, and Waters.
Founder and CEO, Daojing Wang, Ph.D., says he is especially pleased with how customers have embraced the Newomics platform solutions: "We set out to tackle the key challenges in mass spectrometry, including sensitivity, robustness, and throughput. With the product developments by our dedicated team, and through collaborations with global mass spec industry leaders, we have delivered unique mass spec front-end solutions to our customers. We will continue to fulfill customer needs and address the challenges in their mass spectrometry workflows in 2023 and beyond."
Newomics Inc. is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company's products deliver the sensitivity and robustness for superior nanoflow and microflow LC-MS. The plug-and-play MnESI platform (MnESI source + M3 emitter) and DuoESI platform (DuoESI source + M3 emitter + MEA chip) are currently interfaced to diverse MS instruments and can be ordered at www.newomics.com.
These press releases may also interest you